Articles

Podcasts

Videos

Pain

The indication limits the new opioid to clinical setting use—no take-home prescriptions.

FDA Approves Opioid Agonist Oliceridine

The expert-led narrative series will seek to answer when and how the development of opioids led to a public health crisis.

Introducing Painkiller: A History of Crisis

Management of Opioid-Induced Chronic Constipation

Originally approved in 2002, tegaserod (Zelnorm) was withdrawn in 2007 due to potential safety concerns.

FDA Approves Tegaserod Reintroduction for IBS with Constipation

Pharma submits sNDA for IBS-C drug plecanatide.

Synergy Pharmaceuticals Submits NDA for IBS-C Drug Plecanatide

The FDA today approved constipation remedy plecanatide.

Chronic Idiopathic Constipation Gets New FDA Approved Treatment

Patients suffering from irritable bowel syndrome with constipation (IBS-C) may benefit from a new drug, plecanatide, making its way through the approval pipeline.

Promising Results for Experimental Irritable Bowel Syndrome Drug

The new Rome IV criteria classify the functional bowel disorders into five distinct categories, including irritable bowel syndrome (IBS), functional constipation, functional diarrhea, functional abdominal bloating/distention, and unspecified functional bowel disorder. A new category for opioid-induced constipation, which is distinct from the functional bowel disorders, has been added.

Five Categories of Lower Gastrointestinal Functional Bowel Disorders in Revised Rome IV Criteria

Rome IV updates include more specific definitions and diagnostic criteria for functional gastroduodenal disorders such as functional dyspepsia, belching disorders, and nausea and vomiting disorders.

Rome IV Criteria Get Specific about Functional Gastroduodenal Disorders

The Rome Foundation announced the release of updated and revised Rome IV diagnostic criteria for more than 20 different gastrointestinal disorders at DDW 2016.

Opioid-induced Constipation